| Literature DB >> 36076249 |
Thomas J Klein1, Suki Gill1,2, Martin A Ebert1,2, Garry Grogan2,3, Warwick Smith1,2, Zaid Alkhatib2, John Geraghty2, Alison J D Scott2, Alan Brown2, Pejman Rowshanfarzad4.
Abstract
BACKGROUND: The CyberKnife Xsight lung-tracking system (XLTS) provides an alternative to fiducial-based target-tracking systems (FTTS) for non-small-cell lung cancer (NSCLC) patients without invasive fiducial insertion procedures. This study provides a method for 3D independent dosimetric verification of the accuracy of the FTTS compared to the XLTS without relying on log-files generated by the CyberKnife system.Entities:
Keywords: 3D Dosimetry; CyberKnife; Tumor-tracking; Xsight
Mesh:
Year: 2022 PMID: 36076249 PMCID: PMC9461108 DOI: 10.1186/s13014-022-02123-1
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 4.309
Fig. 1The breathing trace used in this study. All treatment deliveries were completed using the same breathing trace
Summary of treatment plans prepared for each of the different target tracking modalities. The treatment modality, whether Synchrony tracking was employed, and the phantom setup used are indicated. The distance between the imaging isocenter and the target centroid was the same for all experiments
| Treatment modality | Synchrony tracking | Phantom setup |
|---|---|---|
| 3-Fiducial static (FTTS) | No | No target rotation |
| 3-Fiducial synchrony (FTTS) | Yes | No target rotation |
| 1-Fiducial synchrony (FTTS) | Yes | No target rotation |
| 3-Fiducial static (FTTS) | No | Target rotation allowed |
| 1-Fiducial synchrony (FTTS) | Yes | Target rotation allowed |
| XLTS 2-view static | No | Target rotation allowed |
| XLTS 2-view | Yes | Target rotation allowed |
| XLTS 1-view | Yes | Target rotation allowed |
| XLTS 0-view | No | Target rotation allowed |
Fig. 2A CT Scan of the QUASAR™ respiratory motion phantom with sternum removed to visualise the target. The target with fiducial markers is also shown more clearly; B Image of the phantom setup as used for treatment delivery; C An example of the reconstructed 3D dose distribution delivered to the lung insert during treatment delivery; D The lung insert used for treatment delivery, illustrating the alternating layers of air-equivalent material with the target embedded and Gafchromic EBT3 film for dose measurement
Gamma pass rates and mean Gamma values for the (3%/3 mm), (3%/2 mm) and (2%/2 mm) criteria for each tested plan
| Treatment modality | Gamma criteria | Gamma passing rate | Mean gamma value |
|---|---|---|---|
3-Fiducial static (No target rotation) (FTTS) | 3%/3 mm | 99.8% | 0.22 |
| 3%/2 mm | 99.3% | 0.29 | |
| 2%/2 mm | 98.6% | 0.33 | |
3-Fiducial synchrony (No target rotation) (FTTS) | 3%/3 mm | 96.7% | 0.30 |
| 3%/2 mm | 93.7% | 0.39 | |
| 2%/2 mm | 92.9% | 0.46 | |
1-Fiducial synchrony (No target rotation) (FTTS) | 3%/3 mm | 99.2% | 0.23 |
| 3%/2 mm | 97.8% | 0.30 | |
| 2%/2 mm | 96.9% | 0.34 | |
3-Fiducial static (Target rotation allowed) (FTTS) | 3%/3 mm | 98.6% | 0.25 |
| 3%/2 mm | 97.1% | 0.33 | |
| 2%/2 mm | 96.3% | 0.38 | |
1-Fiducial synchrony (Target rotation allowed) (FTTS) | 3%/3 mm | 96.3% | 0.36 |
| 3%/2 mm | 91.2% | 0.48 | |
| 2%/2 mm | 87.8% | 0.57 | |
XLTS 2-view static (Target rotation allowed) | 3%/3 mm | 99.9% | 0.22 |
| 3%/2 mm | 99.4% | 0.28 | |
| 2%/2 mm | 98.4% | 0.33 | |
XLTS 2-view synchrony (Target Rotation Allowed) | 3%/3 mm | 97.3% | 0.35 |
| 3%/2 mm | 92.8% | 0.46 | |
| 2%/2 mm | 89.2% | 0.54 | |
XLTS 1-view synchrony (Target ROTATION ALLOWED) | 3%/3 mm | 98.5% | 0.29 |
| 3%/2 mm | 96.2% | 0.38 | |
| 2%/2 mm | 93.44% | 0.44 | |
XLTS 0-View (Target rotation allowed) | 3%/3 mm | 85.0% | 0.55 |
| 3%/2 mm | 76.1% | 0.70 | |
| 2%/2 mm | 69.7% | 0.88 |
Fig. 3Sagittal views of the delivered and TPS-calculated dose distributions and the gamma maps for tested plans using the phantom setup with no target rotation. The Gamma criteria of (3%, 2 mm) is used
Fig. 4Sagittal views of the delivered and TPS-calculated dose distributions and the gamma maps for tested plans using the phantom setup with target rotation. The Gamma criteria of (3%, 2 mm) is used
Fig. 5Sagittal views of the delivered and TPS-calculated dose distributions and the gamma maps for tested plans using the phantom setup with target rotation. The Gamma criteria of (3%, 2 mm) is used